🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
✕
Login
Home
News
Messages
Startup Showcase
Trackers
Premium
Premium Content
Jobs
Notifications
Settings
Try our Valuation Calculator →
Log In
News on Medial
Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO
Business Insider
·
1y ago
Medial
Google DeepMind CEO Demis Hassabis believes that AI-designed prescription drugs could be entering clinical testing within a couple of years. He stated that they have signed deals with Big Pharma and expect to have AI-designed drugs in clinical trials in the near future. While AI has the potential to accelerate drug discovery and provide personalized care, there is a risk of bias if the models are not trained on diverse data sets. Hassabis also referenced Google DeepMind's recent setback with its Gemini AI image generator, which generated historically inaccurate images, leading to the feature being temporarily taken offline.
View Source
Related News
Google DeepMind CEO addresses the Gemini debacle and says image generator could be back in a 'couple of weeks'
Business Insider
·
1y ago
Medial
Google DeepMind CEO Demis Hassabis announced during the Mobile World Conference that the company is planning to relaunch its AI image generator, Gemini, within the next couple of weeks. The tool had been paused after users discovered it was producing historically inaccurate images, such as racially diverse depictions of the US Founding Fathers and Nazis. Hassabis stated that Google DeepMind values historical accuracy and the feature responsible for the inaccuracies has been taken offline to be fixed before being reintroduced.
View Source
How Boltzmann Is Using GenAI To Speed Up Drug Discovery In India
Inc42
·
1y ago
Medial
Boltzmann, an Indian GenAI startup focused on drug discovery, aims to collaborate with major international players in the pharmaceutical space. The Bengaluru-based startup has developed a range of AI platforms, including BoltChem for designing novel drugs and BoltBio for identifying disease causes. Other platforms include ReBolt for optimising R&D processes, BoltPro for protein engineering, and ClinBolt for designing clinical trials. Boltzmann is currently working with Indian drug research institutes and is in talks with top global pharma companies for deploying its platforms. The company is also seeking $3 million in funding and is exploring merger and acquisition opportunities.
View Source
ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia
Entrackr
·
6m ago
Medial
ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia. The proceeds will be used in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market. Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign develops solutions for early detection of oral cancer. The startup also claims to offer India’s first salivary biomarker-based test which can identify pre-cancerous conditions much before visible symptoms emerge. Looking ahead, ErlySign plans to use CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes.
View Source
Japanese pharma Takeda launches innovation centre, eyes to onboard AI-driven talent
Economic Times
·
6m ago
Medial
Japanese pharmaceutical company Takeda has launched its first Innovation Capability Centre in Bengaluru, India. This center aims to employ 750 experts, focusing on AI-driven skills to aid drug discovery, clinical trials, and patient care. Takeda chose Bengaluru for its talent pool and tech ecosystem, planning to develop products to enhance healthcare support. Over the next years, it will focus on inflammation, oncology, and rare diseases, with plans to introduce a Dengue vaccine in India by 2026.
View Source
Instamart CEO sees quick commerce dominate shopping mode in five years - The Economic Times
Economic Times
·
21d ago
Medial
Swiggy Instamart CEO Amitesh Jha predicts that quick commerce will dominate online shopping within five years due to high consumer interest, despite current low market penetration. Speaking at the Indian Healthy Snacking Summit, Jha highlighted the sector's growth, driven by companies like Blinkit, Zepto, and Instamart. He noted quick commerce’s limited shelf space and its role in promoting product trials. The market is expanding, expected to reach Rs 64,000 crore by FY25, growing at a CAGR of 142%.
View Source
Google DeepMind cofounder says AI can act like an entrepreneur and inventor in the next five years
Business Insider
·
1y ago
Medial
Mustafa Suleyman, co-founder of Google's DeepMind, predicts that AI will be capable of creating and running its own business within the next five years. Speaking at the 2024 World Economic Forum, Suleyman believes that AI will possess entrepreneurial, project management, and invention skills, enabling it to market, manufacture, and sell products for profit. He expects these capabilities to become widely available and inexpensive, potentially even in open-source formats, by the end of the decade. Suleyman's comments reflect his ongoing predictions on the societal impact of AI.
View Source
‘It could take time for it to play out:’ CEO Sundar Pichai on Google’s antitrust battles
Livemint
·
10m ago
Medial
Google's CEO, Sundar Pichai, expects the ongoing antitrust challenges faced by Google to continue for several years, stating that they do not pose an immediate risk to the company's operations. Google is currently facing two separate antitrust trials, one regarding its dominance in digital advertising and the other focused on its control of online search. Pichai has mentioned that Google will vigorously defend itself where it believes the challenges harm its ability to innovate on behalf of its users. The legal proceedings are expected to last for years and may bring about significant changes in the tech landscape.
View Source
Bio-tech startup Utopia Therapeutics raises $1.5 Mn led by Whale Tank
Entrackr
·
1m ago
Medial
Utopia Therapeutics, a biotech company developing next-generation vaccines for chronic metabolic diseases, has secured $1.5 million in seed funding from Whale Tank. The proceeds will be utilized to accelerate the preclinical development of UT009, its lead immunotherapeutic candidate targeting obesity and support the advancement of UT009 toward regulatory toxicology studies, IND-enabling milestones, and Phase I human clinical trials, Utopia Therapeutics said in a press release. Co-founded in 2024 by Uday Saxena and Gopi Kadiyala, Utopia Therapeutics focuses on developing next-generation vaccines for chronic metabolic diseases, particularly obesity. The startup aims to deliver first-in-class vaccines for obesity and related metabolic diseases using novel scientific approaches. “Obesity is a global epidemic with limited long-term therapeutic options. UT009 represents a paradigm shift by differentiating it from current obesity drugs by addressing the root causes of weight gain. This investment enables us to move swiftly toward clinical translation,” said Uday Saxena and Gopi Kadiyala, co-founders of Utopia Therapeutics. According to the Hyderabad-based company, UT009 is a novel vaccine designed to reduce fat accumulation and improve metabolic health by targeting lipid-associated antigens. The company plans to scale up and commercialize Utopia’s UT018-based regenerative product line, built on GRAS-qualified, non-pharmaceutical applications.
View Source
Wockhardt flying high, extends uptrend to 12th consecutive session
Money Control
·
1y ago
Medial
Wockhardt shares have surged by nearly 80 percent in the last month, reaching a new 52-week high. The company's positive outlook is driven by its upcoming launch of two antibiotics that are expected to have a significant impact on its earnings. Nafithromycin, a treatment for pneumonia, is awaiting approval and is projected to capture market share from the current leading drug. The company has secured patents for this drug, providing a favourable time frame for its research and development efforts. Another antibiotic, Zaynich, is also showing promising results in its phase 3 trials. Wockhardt aims to launch both drugs in the next few years, targeting a sizable market value.
View Source
Bank of America expects India fundraising to be busier than ever
Livemint
·
1y ago
Medial
Bank of America predicts that fundraising activity in India will be robust over the next couple of years. The country's conglomerates, tech firms, and financial services providers are seeking capital for growth, while company owners are looking to sell holdings. Initial public offerings (IPOs) are expected to be particularly active in 2024 and 2025, with 5 to 10 tech firms and a few subsidiaries of multinational companies planning to launch IPOs during this period. Factors such as a growing retail investor base, a strong economy, and global investors shifting focus from China to India are contributing to this trend.
View Source
Trackers
Active Indian VC’s
OG Capital
Email
With a hands-on approach, OG Capital aims to invest in over 20 promising...
Accel Partners
Email
Early and growth-stage investments in disruptive technology companies with...
Blume
Email
Early-stage venture capital firm investing in technology startups in India. Focus on...
Access All Trackers
Startup Showcase Winners
June 2025
Buddy
Helping your parents when you are miles away
BiteStop
The Pit Stop Your Cravings Deserve
Bloomer
The next generation E-commerce platform
Enter Ongoing Startup Showcase
Top Users
Trending News on Medial
Download the medial app to read full posts, comements and news.
Go to Medial App
Not Now
Know everything that’s happening in the startup ecosystem, first.
Enable Notifications?
No, thanks
Count me in
